Transplantation immunology

JAMA

Volumn 278, Issue 22, 1997, Pages 1993-1999

  VanBuskirk, Anne M ^a   Pidwell, Diane J ^a   Adams, Patrick W ^a   Orosz, Charles G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOPATHOLOGY; IMMUNITY; INCIDENCE; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR;

EID: 0031467616     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1993     Document Type: Review

References (72)

1. Hall BM. Cells mediating allograft rejection. Transplantation. 1991;51:1141-1151.
2. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol. 1992;10:333-358.
3. Hall BM, Dorsch SE. Cells mediating allograft rejection. Immunol Rev. 1984;77:32-59.
4. Bradley JA, Bolton EM. The T cell requirements for allograft rejection. Transplant Rev. 1992;6:115-129.
5. VanBuskirk AM, Wakely ME, Orosz CG. Acute rejection of cardiac allografts by noncytolytic CD4+ T cell populations. Transplantation. 1996;62:300-302.
6. Schulz M, Schuurman H, Joergensen J, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Em J Immunol. 1995;25:474-480.
7. Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation. 1997;63:619-624.
8. Orosz CG. Networked alloimmunity: a brief reexamination of some basic concepts in transplantation immunobiology. J Heart Lung Transplant. 1996;15:1063-1068.
9. Azuma H, Tilney NL. Immune and nonimmune mechanisms of chronic rejection of kidney allografts. J Heart Lung Transplant. 1995;14:S136-S142.
10. Krensky AM. The HLA system, antigen processing and presentation. Kidney Int. 1997;51(suppl 58):S2-S7.
11. Gill RG, Coulombe M, Lafferty KJ. Pancreatic islet allograft immunity and tolerance: the two-signal hypothesis revisited. Immunol Rev. 1996;149: 75-96.
12. Zelenock GB, D'Alecy LG. Tissue ischemia. In: Greenfield JB, Mulholland MW, Oldham KT, Zelenock GB, eds. Surgery: Scientific Principles and Practice. Philadelphia, Pa: JB Lippincott Co; 1993: 1500-1511.
13. Cotran RS, Kumar V, Robbins SL. Inflammation and repair. In: Cotran RS, Kumar V, Robbins S, Schoen F, eds. Pathologic Basis of Disease. Philadelphia, Pa: WB Saunders Co; 1994:51-92.
14. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNFα-independent IL-8 secretion and E-selectin expression. J Immunol. 1997;158: 5435-5441.
15. Toossi Z, Sedor JR, Mettler M, Everson B, Young T, Ratnoff OD. Induction of expression of monocyte interleukin-1 by Hageman factor (factor XII). Proc Natl Acad Sci U S A. 1992;89:11969-11972.
16. Simmons RL, Ildstad ST, Smith CR, Reemtsma K, Najarian JS. Transplantation. In: Schwartz SI, Shires GT, Spencer FC, Husser WCH, eds. Principles of Surgery. New York, NY: McGraw-Hill; 1994:377-454.
17. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine stategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269: 1829-1835.
18. Lider O, Hershkoviz R, Kachalsky SG. Interactions of migrating T lymphocytes, inflammatory mediators, and the extracellular matrix. Crit Rev Immunol. 1995;15:271-283.
19. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem. 1990;59: 253-288.
20. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993;364: 33-39.
21. Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994;368:215-221.
22. Helene M, Lake-Bullock MHV, Bryson JS, Jennings CD, Kaplan AM. Inhibition of graft-versus-host disease: use of a T cell-controlled suicide gene. J Immunol. 1997;158:5079-5082.
23. Rammensee H, Falk K, Rotzschke O. MHC molecules as peptide receptors. Curr Opin Immunol. 1993;5:35-44.
24. Chien Y, Davis MM. How alpha/beta T-cell receptors 'see' peptide/MHC complexes. Immunol Today. 1993;14:597-602.
25. Rotzschke O, Falk K. Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol Today. 1991; 12:447-455.
26. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351:290-296.
27. VanBuskirk AM, Brown DJ, Adams PW, Orosz CG. The MHC and allograft rejection. In: Mohanakumar T, ed. The Role of MHC and Non-MHC Antigens in Allograft Immunity. Georgetown, Tex: RG Landes Co; 1994:27-71.
28. Germain RN. Antigen processing and presentation. In: Paul WE, ed. Fundamental Immunology. New York, NY: Raven Press; 1993:629-670.
29. Bluestone JA. Costimulation and its role in organ transplantation. Clin Transplant. 1996;10:104-109.
30. Mondino A, Jenkins MK. Surface proteins involved in T cell costimulation. J Leukoc Biol. 1994; 55:805-815.
31. Johnson JG, Jenkins MK. Accessory cell-derived signals required for T cell activation. Immunol Res. 1993;12:48-64.
32. Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol. 1996;157:3280-3289.
33. Hintzen RQ, Lens SMA, Lammers K, Kuiper H, Beckmann MP, Van Lier RAW. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol. 1995;154:2612-2623.
34. Daynes RA, Araneo BA. Programming of lymphocyte responses to activation: extrinsic factors, provided microenvironmentally, confer flexibility and compartmentalization to T cell function. Chem Immunol. 1992;54:1-20.
35. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med. 1994;180:1715-1728.
36. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of TH2-like effector cells in peripheral tolerance. Transplantation. 1992;53:1281-1294.
37. VanBuskirk AM, Wakely ME, Orosz CG. Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation. 1996;62: 229-238.
38. Bradley JA. Indirect T cell recognition in allograft rejection. Int Rev Immunol. 1996;13:245-255.
39. Lu CY, Khair-el-Din TA, Dawidson IA, et al. Xenotransplatation. FASEB J. 1994;8:1122-1130.
40. Dalmasso AP. The complement system in xenotransplantation. Immunopharmacology. 1992;24: 149-160.
41. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today. 1990;11:364-371.
42. Scornik JC, Brunson ME, Howard RJ, Pfaff WW. Alloimmunization, memory, and the interpretation of crossmatch results for renal transplantation. Transplantation. 1992;54:389-394.
43. Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum Immunol. 1989;26:245-260.
44. Beatty P. Histocompatibility assessment in bone marrow transplantation. In: Rose N, Macario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society of Microbiology; 1997:1123-1131.
45. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol. 1994; 153:3791-3803.
46. Chapman JR, Taylor CJ, Ting A, Morres PJ. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Transplantation. 1986;42:608-613.
47. Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol. 1997;17: 1-32.
48. MacGregor MS, Bradley JA. Overview of immunosuppressive therapy in organ transplantation. Br J Hosp Med. 1995;54:276-282.
49. Przepiorka D. Rational use of new immunosuppressive agents. In: Sollinger H, Przepiorka D, eds. Recent Developments in Transplantation Medicine, Volume I: New Immunosuppressive Drugs. Glenview, Ill: Physicians & Scientists Publishing Co Inc; 1994:1-7.
50. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol. 1996;8:710-720.
51. Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): mechanisms of action and effects in transplantation. Transplant Rev. 1993;7:129-139.
52. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-551.
53. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation. 1996;61:722-729.
54. Hayry P, Mennander A, Raisanen-Sokolowski A, et al. Pathophysiology of vascular wall changes in chronic allograft rejection. Transplant Rev. 1993;7:1-20.
55. Armstrong AT, Strauch AR, Starling RC, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac allografts. Transplantation. 1997;63:941-947.
56. Tullius SG, Tilney NL. Both alloantigen-dependent and independent factors influence chronic allograft rejection. Transplantation. 1995;59:313-318.
57. Orosz CG, Sedmak DD, Ferguson RM. Transplant Vascular Sclerosis. Georgetown, Tex: RG Landes Co; 1995:1-251.
58. Orosz CG, Bergese SD, Wakely ME, Xia D, Gordillo GM, VanBuskirk AM. Acute versus chronic graft rejection: related manifestations of allosensitization in graft recipients. Transplant Rev. 1997; 11:38-50.
59. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation. 1994;57:68-72.
60. Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 1991;10: 45-49.
61. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331-338.
62. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55:752-757.
63. Orosz CG. Local cellular immunology of experimental transplant vascular sclerosis. Clin Transplant. 1996;10:100-103.
64. Rose EA, Smith CR, Petrossian GA, Barr ML, Reemtsma K. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery. 1989;106: 203-207.
65. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response, II: clinical and pathologic features of renal transplants with anti-class 1-like antibody. Transplantation. 1992; 53:550-555.
66. Lobo PI, Spencer CE, Stevenson WC, Pruett TL. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation. 1995;59:357-360.
67. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts, II: importance of humoral immunity. J Immunol. 1994;152:5135-5141.
68. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation. 1993;55: 993-995.
69. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation. 1994;57:857-859.
70. Wahlers T, Mugge A, Oppelt P, et al. Preventive treatment of coronary vasculopathy in heart transplantation by inhibition of smooth muscle cell proliferation with angiopeptin. J Heart Lung Transplant. 1995;14(1, pt 1):143-150.
71. Clement JD, Chan SY, Bishop DK. Allogeneic class I MHC requirement for alloantigen-reactive helper T-lymphocyte responses in vivo. Transplantation. 1996;62:388-396.
72. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276: 1719-1724.